Pure red cell aplasia after hematopoietic stem cell transplantation - experimental therapeutic approaches

References

• Means RT. Pure red cell aplasia. Blood. 2016;128(21):2504.
   PubMed Web of Science ®Google Scholar
• Gunes G, Malkan UY, Yasar HA, et al. Clinicopathological associations of acquired erythroblastopenia. Int J Clin Exp Med. 2015;8(12):22515–22519.
   PubMed Web of Science ®Google Scholar
• Longval T, Galimard JE, Leprêtre AC, et al. Treatment for pure red cell aplasia after major ABO-incompatible allogeneic stem cell transplantation: a multicentre study. Br J Haematol. 2021 May;193(4):814–826.
   PubMed Web of Science ®Google Scholar
• Kimura F, Sato K, Kobayashi S, et al. Impact of AB0-blood group incompatibility on the outcome of recipients of bone marrow transplants from unrelated donors in the Japan marrow donor program. Haematologica. 2008 November;93(11):1686–1693.
   PubMed Web of Science ®Google Scholar
• Rowley SD, Donato ML, Bhattacharyya P. Red blood cell-incompatible allogeneic hematopoietic progenitor cell transplantation. Bone Marrow Transplant. 2011 September;46(9):1167–1185.
   PubMed Web of Science ®Google Scholar
• Aung FM, Lichtiger B, Bassett R, et al. Incidence and natural history of pure red cell aplasia in major ABO-mismatched haematopoietic cell transplantation. Br J Haematol. 2013 March;160(6):798–805.
   PubMed Web of Science ®Google Scholar
• Helbig G, Stella-Holowiecka B, Wojnar J, et al. Pure red-cell aplasia following major and bi-directional ABO-incompatible allogeneic stem-cell transplantation: recovery of donor-derived erythropoiesis after long-term treatment using different therapeutic strategies. Ann Hematol. 2007 September;86(9):677–683.
   PubMed Web of Science ®Google Scholar
• Marco-Ayala J, Gómez-Seguí I, Sanz G, et al. Pure red cell aplasia after major or bidirectional ABO incompatible hematopoietic stem cell transplantation: to treat or not to treat, that is the question. Bone Marrow Transplant. 2021 April;56(4):769–778.
   PubMed Web of Science ®Google Scholar
• Migdady Y, Pang Y, Kalsi SS, et al. Post-hematopoietic stem cell transplantation immune-mediated anemia: a literature review and novel therapeutics. Blood Advances. 2022;6(8):2707–2721.
   PubMed Web of Science ®Google Scholar
• Hirokawa M, Fukuda T, Ohashi K, et al. Efficacy and long-term outcome of treatment for pure red cell aplasia after allogeneic stem cell transplantation from major ABO-incompatible donors. Biol Blood Marrow Transplant. 2013 2013 July 01;19(7):1026–1032.
   PubMed Web of Science ®Google Scholar
• Lee JH, Lee JH, Choi SJ, et al. Changes of isoagglutinin titres after ABO-incompatible allogeneic stem cell transplantation. Br J Haematol. 2003 February;120(4):702–710.
   PubMed Web of Science ®Google Scholar
• Griffith LM, McCoy JPsJr., Bolan CD, et al. Persistence of recipient plasma cells and anti-donor isohaemagglutinins in patients with delayed donor erythropoiesis after major ABO incompatible non-myeloablative haematopoietic cell transplantation. Br J Haematol. 2005 March;128(5):668–675.
   PubMed Web of Science ®Google Scholar
• Sahovic EA, Flick J, Graham CD, et al. Case report: isoimmune inhibition of erythropoiesis following ABO-incompatible bone marrow transplantation. Am J Med Sci. 1991 December;302(6):369–373.
   PubMed Web of Science ®Google Scholar
• Selleri C, Raiola A, De Rosa G, et al. CD34+-enriched donor lymphocyte infusions in a case of pure red cell aplasia and late graft failure after major ABO-incompatible bone marrow transplantation. Bone Marrow Transplant. 1998 September;22(6):605–607.
   PubMed Web of Science ®Google Scholar
• Bolan CD, Leitman SF, Griffith LM, et al. Delayed donor red cell chimerism and pure red cell aplasia following major ABO-incompatible nonmyeloablative hematopoietic stem cell transplantation. Blood. 2001 September 15 98(6):1687–1694.
   PubMed Web of Science ®Google Scholar
• Mielcarek M, Leisenring W, Torok-Storb B, et al. Graft-versus-host disease and donor-directed hemagglutinin titers after ABO-mismatched related and unrelated marrow allografts: evidence for a graft-versus-plasma cell effect. Blood. 2000 August 1 96(3):1150–1156.
   PubMed Web of Science ®Google Scholar
• Martino R, García-Cadenas I, Esquirol A. Daratumumab may be the most effective treatment for post-engraftment pure red cell aplasia due to persistent anti-donor isohemagglutinins after major ABO-mismatched allogeneic transplantation. Bone Marrow Transplant. 2021 October;28:1–4.
   Google Scholar
• Lee JH, Lee KH, Kim S, et al. Anti-A isoagglutinin as a risk factor for the development of pure red cell aplasia after major ABO-incompatible allogeneic bone marrow transplantation. Bone Marrow Transplant. 2000 January;25(2):179–184.
   PubMed Web of Science ®Google Scholar
• Busca A, Dellacasa C, Giaccone L, et al. Eltrombopag for the treatment of refractory pure RBC aplasia after major ABO incompatible hematopoietic stem cell transplantation. Biol Blood Marrow Transplant. 2018 August;24(8):1765–1770.
   PubMed Web of Science ®Google Scholar
• Gao Y, Gao F, Shi J, et al. Successful treatment of refractory pure red cell aplasia with eltrombopag after ABO-incompatible allogeneic hematopoietic stem cell transplantation. J Zhejiang Univ Sci B. 2021;22(8):695–700.
   PubMed Web of Science ®Google Scholar
• Liu X, Cheng L, He Y, et al. Eltrombopag restores erythropoiesis in refractory adult acquired pure red cell aplasia. Int J Hematol. 2021 2021 July 01;114(1):124–128.
   PubMed Web of Science ®Google Scholar
• Stussi G, Halter J, Bucheli E, et al. Prevention of pure red cell aplasia after major or bidirectional ABO blood group incompatible hematopoietic stem cell transplantation by pretransplant reduction of host anti-donor isoagglutinins. Haematologica. 2009 February;94(2):239–248.
   PubMed Web of Science ®Google Scholar
• Damodar S, George B, Mammen J, et al. Pre-transplant reduction of isohaemagglutinin titres by donor group plasma infusion does not reduce the incidence of pure red cell aplasia in major ABO-mismatched transplants. Bone Marrow Transplant. 2005 August;36(3):233–235.
   PubMed Web of Science ®Google Scholar
• Poon LM, Koh LP. Successful treatment of isohemagglutinin-mediated pure red cell aplasia after ABO-mismatched allogeneic hematopoietic cell transplant using bortezomib. Bone Marrow Transplant. 2012 June;47(6):870–871.
   PubMed Web of Science ®Google Scholar
• Henig I, Yehudai-Ofir D, Zohar Y, et al. Pure red cell aplasia following ABO-mismatched allogeneic hematopoietic stem cell transplantation: resolution with daratumumab treatment. Acta Haematol. 2021;144(6):683–687.
   PubMed Web of Science ®Google Scholar
• Asawapanumas T, Chanswangphuwana C, Watanaboonyongcharoen P, et al. Daratumumab as a frontline immunosuppression for pure red cell aplasia after major ABO-mismatched allogeneic hematopoietic stem cell transplantation. Leuk Res Rep. 2022;17:100314.
   PubMedGoogle Scholar
• Vo AK, Kollsete Gjelberg H, Hovland R, et al. Pure red cell aplasia with del(20q) sensitive for immunosuppressive treatment. Case Rep Hematol. 2020;2020:1262038.
   PubMed Web of Science ®Google Scholar
• Deaglio S, Mehta K, Malavasi F. Human CD38: a (r)evolutionary story of enzymes and receptors. Leuk Res. 2001 [2001 January 01];25(1):1–12.
   PubMed Web of Science ®Google Scholar